AAP
IKT icon

Arax Advisory Partners’s Inhibikase Therapeutics IKT Stock Holding History

Arax Advisory Partners’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$82 Buy
+49
New +$87 ﹤0.01% 3629
2025
Q4 		– Sell
-86
Closed -$139 – 4294
2025
Q3 		$139 Buy
+86
New +$149 ﹤0.01% 3477

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Arax Advisory Partners's IKT Position: Q1 2026 in Review

Arax Advisory Partners opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 49 shares worth $82. The stake represents ﹤0.01% of the portfolio and ranks #3629 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in IKT as recently as Q3 2025.

Arax Advisory Partners first reported a position in IKT in Q3 2025 and has held it in 2 quarters since. The position peaked at $139 in Q3 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Arax Advisory Partners held 49 shares of Inhibikase Therapeutics worth $82 as of Q1 2026.
  • Inhibikase Therapeutics was a new Arax Advisory Partners position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3629 holding.
  • Arax Advisory Partners first reported a position in Inhibikase Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's Inhibikase Therapeutics position peaked at $139 in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.